Liang, Y., Mafuvadze, B., Besch-Williford, C., & Hyder, S. M. (2018). A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts. Breast Cancer (Dove Med Press).
Chicago Style aipamenaLiang, Yayun, Benford Mafuvadze, Cynthia Besch-Williford, and Salman M. Hyder. "A Combination of P53-activating APR-246 and Phosphatidylserine-targeting Antibody Potently Inhibits Tumor Development in Hormone-dependent Mutant P53-expressing Breast Cancer Xenografts." Breast Cancer (Dove Med Press) 2018.
MLA aipamenaLiang, Yayun, Benford Mafuvadze, Cynthia Besch-Williford, and Salman M. Hyder. "A Combination of P53-activating APR-246 and Phosphatidylserine-targeting Antibody Potently Inhibits Tumor Development in Hormone-dependent Mutant P53-expressing Breast Cancer Xenografts." Breast Cancer (Dove Med Press) 2018.